Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment

Reuters10-21

Spero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment

Spero Therapeutics Inc. and GSK plc have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548667-en) on October 21, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577843740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577843740","market":"fut","top_or_hot":-1,"title":"Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a> and <a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548667-en) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-21 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRO\">Spero Therapeutics Inc.</a> and <a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548667-en) on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL7vv9hM:1","article_id":"2577843740","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577843740","pubTimestamp":1761026448,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spero Therapeutics Inc. and GSK plc have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections , including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","SPRO":"Spero Therapeutics Inc.","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股"},"translate_title":"Spero Therapeutics报告口服抗生素HBr替比培南治疗cUTI取得3期成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SPRO":0.9},"content_text":"Spero Therapeutics Reports Phase 3 Success for Oral Antibiotic Tebipenem HBr in cUTI Treatment\n    \n\nSpero Therapeutics Inc. and GSK plc have announced positive efficacy and safety results from the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The results were presented on October 20, 2025, during a late-breaking oral abstract session at IDWeek 2025 in Atlanta, Georgia. The trial met its primary endpoint, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous imipenem-cilastatin. Secondary endpoints showed clinical cure rates of 93.5% for tebipenem HBr and 95.2% for imipenem-cilastatin, as well as similar microbiological response rates. Spero and GSK plan to submit the data to regulatory authorities in Q4 2025. If approved, tebipenem HBr would be the first oral carbapenem antibiotic available in the US for patients with cUTIs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9548667-en) on October 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577843740","isCrawlerRequest":true}